Dr Daniel Scott
PhD, BBiomedSc, BSc (Hons)

Daniel completed his PhD at The University of Melbourne in 2007, working on the newly discovered relaxin receptor RXFP1.

In 2008 he was awarded an NHMRC CJ Martin Fellowship, allowing him to work as a postdoctoral researcher in the laboratory of Prof. Andreas Plückthun in Zurich, Switzerland. While in Zurich he invented a novel method, called CHESS, for the directed evolution of detergent-resistant membrane proteins.

GPCRs stabilised with this method can be produced recombinantly in bacteria, purified in detergents and experimentally probed as if they were highly stable soluble proteins. Such stabilised GPCRs can be applied to X-ray crystallography and NMR for structural studies, but can also be used to probe the molecular determinants of ligand binding, ligand-receptor selectivity and for drug discovery.

The CHESS technology was spun out into a Swiss biotechnology company, called G7 therapeutics, co-founded by Daniel in 2013. In 2016 G7 therapeutics was acquired by the UK pharmaceutical company, Heptares Therapeutics. In November 2011 Dr Scott took up a group leader position at the Florey Institute of Neuroscience and Mental Health. During 2012-13 Dr Scott setup his new laboratory to perform GPCR engineering, recruited new students and staff and established new research projects focused on understanding the molecular mechanisms underlying drug action at GPCRs.

Dr Scott also actively applies his expertise to invent, and improve, existing technologies used in other fields. An example of this is the engineering of an ultra-stable fluorescent protein, called muGFP, which allowed improved imaging of cleared-whole rodent brains to assist in mapping neuronal networks (Scott et al, Scientific Reports 2018)

Key collaborators:

Prof. Ross Bathgate - Florey
A. Prof. Paul Gooley - UoM, Biochem. and Mol. Biol.
Prof. Arthur Christopoulos - MIPS
Prof. Andreas Plückthun - University of Zurich
Dr Michael Griffin - UoM, Biochem. and Mol. Biol.
Dr David Thal - MIPS
Dr Nicholas Veldhuis - MIPS
Dr David Chalmers - MIPS

  • Location

    Florey Institute of Neuroscience and Mental Health
    30 Royal Parade


Awards and achievements

2018 - NHMRC Project grant (Resolving and targeting the complex molecular mechanisms underlying GPCR signalling)

2018 - NHMRC Project grant (Adenosine A1 receptor modulation: Structure, dynamics & novel pharmacological interventions)

2017 - NHMRC Boosting Dementia Research Leadership Fellow (Targeting GPCRs in Alzheimer's Disease)

2016 - NHMRC Project grant (Unravelling the binding and activation mechanism of complex G Protein-coupled receptor)

2016 - Heptares Therapeutics acquires G7 Therapeutics

2015 - NHMRC Project grant (Understanding mechanisms of allostery and biased agonism at the adenosine A1 receptor)

2015 - NHMRC Project grant (Novel approaches to understanding peptide G-protein-coupled receptor activation)

2015 - NHMRC Project grant (Stabilising G protein-coupled receptors for drug discovery)

2014 - Crystal structures of CHESS-stabilized neurotensin receptor variants solved

2013 - Australasian Society of Clinical and Experimental Pharmacology and Toxicology (ASCEPT) Denis Wade Johnson & Johnson New Investigator Award

2013 - British Pharmacological Society (BPS)/ASCEPT Outstanding Young Investigator Prize

2013 - Co-founded G7 Therapeutics AG, Switzerland

2011 - Recruited to The Florey Institute of Neuroscience and Mental Health as a junior group leader

2010 - Invented the Cellular High Throughput Encapsulation, Solubilization and Screening (CHESS) method

2010 - University of Zurich Postdoctoral Fellowship, group of Andreas Plückthun, Zurich, Switzerland

2008 - NHMRC C.J. Martin Postoctoral Fellow, group of Andreas Plückthun, Zurich, Switzerland (Directed evolution of stabilised G protein-coupled receptors)

Research Papers

Showing 10 of 55. VIEW ALL

Showing 10 of 55. VIEW ALL

Support us

Brain health affects all Australians.
You can support our research by making a donation or a bequest.


Latest breakthroughs, news, events & more.